<code id='7B82EE4274'></code><style id='7B82EE4274'></style>
    • <acronym id='7B82EE4274'></acronym>
      <center id='7B82EE4274'><center id='7B82EE4274'><tfoot id='7B82EE4274'></tfoot></center><abbr id='7B82EE4274'><dir id='7B82EE4274'><tfoot id='7B82EE4274'></tfoot><noframes id='7B82EE4274'>

    • <optgroup id='7B82EE4274'><strike id='7B82EE4274'><sup id='7B82EE4274'></sup></strike><code id='7B82EE4274'></code></optgroup>
        1. <b id='7B82EE4274'><label id='7B82EE4274'><select id='7B82EE4274'><dt id='7B82EE4274'><span id='7B82EE4274'></span></dt></select></label></b><u id='7B82EE4274'></u>
          <i id='7B82EE4274'><strike id='7B82EE4274'><tt id='7B82EE4274'><pre id='7B82EE4274'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:89445

          Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

          advertisement

          For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          comprehensive

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Astellas still sees hope in its gene therapy after four deaths
          Astellas still sees hope in its gene therapy after four deaths

          AdobeAgenetherapystudy,haltedwhenfourchildrenwitharareneuromusculardisorderdiedaftertreatment,showed

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          Condition critical? Britain's beloved but battered National Health Service turns 75

          Britain'sPrimeMinisterRishiSunakspeaks,duringtheNHSanniversaryceremonyatWestminsterAbbey,partofthehe